...
首页> 外文期刊>Respiratory Medicine Case Reports >A case of allergic bronchopulmonary aspergillosis with marked peripheral blood eosinophilia successfully treated with benralizumab
【24h】

A case of allergic bronchopulmonary aspergillosis with marked peripheral blood eosinophilia successfully treated with benralizumab

机译:用贝纳里亚姆成功处理具有标记外周血嗜酸性粒细胞菌的过敏性支气管瓣病虫病的病症

获取原文
   

获取外文期刊封面封底 >>

       

摘要

We herein report a case of allergic bronchopulmonary aspergillosis (ABPA) with marked eosinophilia and high attenuation mucus (HAM) on chest computed tomography (CT), which demonstrated a rapid and remarkable improvement with benralizumab treatment. A 67-year-old Japanese woman, who was diagnosed with asthma at the age of 64 years, was admitted with dyspnea. Her blood test results showed marked eosinophilia (peripheral blood eosinophil count 24403/μL) and elevated serum IgE levels. Chest CT also revealed ground-glass opacity. Sputum cytology detected filamentous fungi, suggesting an infection withAspergillus spp. Based on these findings, ABPA was diagnosed. Following systemic corticosteroid treatment, her respiratory symptoms and chest radiography findings showed improvements. However, with the gradual tapering and eventual discontinuance of the corticosteroid therapy, a concomitant increase in the peripheral blood eosinophils and a recurrence of the clinical symptoms, was observed. In addition, her pulmonary function decreased and chest CT revealed worsened bronchial mucus plugs. To control the asthma with ABPA exacerbation, benralizumab was administered. Following treatment with benralizumab, the patient's asthmatic symptoms improved, together with a decrease in her peripheral eosinophil count. Mucus plugs were no longer visible on chest CT. Pulmonary function test result also showed a remarkable improvement. There was no relapse of dyspnea and no reappearance of the mucus plugs. This case suggests that benralizumab may be a suitable treatment option for patients with ABPA with marked eosinophilia and HAM on chest CT.
机译:本文在此情况下报告了具有明显的嗜酸性粒细胞和高衰减粘液(CH)的过敏性支气管瓣病虫病(ABPA)对胸部计算机断层扫描(CT)的高衰减粘液(CH),其表现出与Benralizumab治疗的快速而显着的改善。 64岁时被诊断出患有哮喘的67岁的日本妇女,涉及呼吸困难。她的血液测试结果显示出明显的嗜酸性粒细胞(外周血嗜酸性粒细胞计数24403 /μl)和血清IgE水平升高。胸部CT还透露了磨碎的玻璃不透明。痰细胞学检测到丝状真菌,表明患有血红蛋白的感染。基于这些发现,ABPA被诊断出来。遵循全身皮质类固醇治疗,她的呼吸系统症状和胸部射线照相结果显示出改善。然而,随着皮质类固醇治疗的逐渐逐渐变细,最终停止,观察到外周血嗜酸性粒细胞的伴随增加和临床症状的复发。此外,她的肺功能下降,胸部CT显示出恶化的支气管粘液塞。为了控制ABPA Exacterbation的哮喘,施用了Benralizumab。在患有本土的治疗后,患者的哮喘症状改善,同时随着她周围嗜酸性粒细胞计数的降低。在胸部CT上不再可见粘液塞。肺功能测试结果也显示出显着的改进。呼吸困难没有复发,没有粘液塞的重新出现。这种情况表明,Benpaizumab可能是ABPA患者的合适的治疗选择,其中嗜酸性粒细胞和胸部CT上的嗜酸性粒细胞和火腿。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号